The weight-loss drug divide: private prescribing is lowest where need is greatest

By Rachel Woods, Associate Professor of Medical Education, University of Nottingham; University of Lincoln

For many people living with obesity, Wegovy and Mounjaro offer the possibility of substantial weight loss without surgery. Yet data from one private provider points to a troubling divide: prescription rates of these drugs in England are lowest in communities where obesity is most common.

Wegovy contains semaglutide, which acts on the GLP-1 hormone pathway involved in appetite. Mounjaro contains tirzepatide, which targets both GLP-1 and another hormone pathway called…

Read complete article

~	“Racial violence is accelerating and we must resist”

~	Lebanon: New media law makes progress but leaves serious free expression gaps

~	Durban Conference 25 years on. Mandi Mudarikwa: “It’s up to us all to build the kind of world we want to live in”

~	Politics with Michelle Grattan: Chris Bowen on co-hosting COP and Australia’s renewables target

~	Noise exposure is linked to chronic stress and heart disease. It’s time to make peace and quiet a public health right

~	Blanche d'Alpuget leaves a lasting imprint on Australian literature – and politics

~	Andrew Hastie denounces Pauline Hanson and Barnaby Joyce as ‘lying cowards’

~	‘Peaceful’ Sweden once sought nuclear weapons. That legacy still shapes defence planning

~	Lebanon/Israel: Hezbollah’s Use of Cluster Munitions

~	‘It was just pure hatred’: a new report reveals intensifying attacks against LGBTQIA+ people